KYMR Quote, Financials, Valuation and Earnings

Catalyst Pharmaceuticals has a net margin of -296.75% compared to Kymera Therapeutics's net margin of 40.12%. Kymera Therapeutics's return on equity of -30.8% beat Catalyst Pharmaceuticals's return on equity of 29.43%.

Kymera Therapeutics has a consensus price target of $62.32, signalling upside risk potential of 32.19%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of $34.29 which suggests that it could grow by 59.17%. Given that Catalyst Pharmaceuticals has higher upside potential than Kymera Therapeutics, analysts believe Catalyst Pharmaceuticals is more attractive than Kymera Therapeutics.

Kymera Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.721, suggesting its less volatile than the S&P 500 by 27.922%.

Kymera Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kymera Therapeutics pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

Kymera Therapeutics quarterly revenues are $22.1M, which are smaller than Catalyst Pharmaceuticals quarterly revenues of $141.4M. Kymera Therapeutics's net income of -$65.6M is lower than Catalyst Pharmaceuticals's net income of $56.7M. Notably, Kymera Therapeutics's price-to-earnings ratio is -- while Catalyst Pharmaceuticals's PE ratio is 13.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kymera Therapeutics is 61.95x versus 5.07x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

CEL-SCI has a net margin of -296.75% compared to Kymera Therapeutics's net margin of --. Kymera Therapeutics's return on equity of -30.8% beat CEL-SCI's return on equity of --.

Kymera Therapeutics has a consensus price target of $62.32, signalling upside risk potential of 32.19%. On the other hand CEL-SCI has an analysts' consensus of $8.00 which suggests that it could grow by 9859.5%. Given that CEL-SCI has higher upside potential than Kymera Therapeutics, analysts believe CEL-SCI is more attractive than Kymera Therapeutics.

Kymera Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.271, suggesting its less volatile than the S&P 500 by 72.891%.

Kymera Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kymera Therapeutics pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

Kymera Therapeutics quarterly revenues are $22.1M, which are larger than CEL-SCI quarterly revenues of --. Kymera Therapeutics's net income of -$65.6M is lower than CEL-SCI's net income of -$6.6M. Notably, Kymera Therapeutics's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kymera Therapeutics is 61.95x versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

Exelixis has a net margin of -296.75% compared to Kymera Therapeutics's net margin of 28.74%. Kymera Therapeutics's return on equity of -30.8% beat Exelixis's return on equity of 29.53%.

Kymera Therapeutics has a consensus price target of $62.32, signalling upside risk potential of 32.19%. On the other hand Exelixis has an analysts' consensus of $44.16 which suggests that it could grow by 1.44%. Given that Kymera Therapeutics has higher upside potential than Exelixis, analysts believe Kymera Therapeutics is more attractive than Exelixis.

Kymera Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Exelixis has a beta of 0.280, suggesting its less volatile than the S&P 500 by 71.957%.

Kymera Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exelixis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kymera Therapeutics pays -- of its earnings as a dividend. Exelixis pays out -- of its earnings as a dividend.

Kymera Therapeutics quarterly revenues are $22.1M, which are smaller than Exelixis quarterly revenues of $555.4M. Kymera Therapeutics's net income of -$65.6M is lower than Exelixis's net income of $159.6M. Notably, Kymera Therapeutics's price-to-earnings ratio is -- while Exelixis's PE ratio is 19.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kymera Therapeutics is 61.95x versus 5.53x for Exelixis. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -296.75% compared to Kymera Therapeutics's net margin of 26.7%. Kymera Therapeutics's return on equity of -30.8% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Kymera Therapeutics has a consensus price target of $62.32, signalling upside risk potential of 32.19%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $727.21 which suggests that it could grow by 39.24%. Given that Regeneron Pharmaceuticals has higher upside potential than Kymera Therapeutics, analysts believe Regeneron Pharmaceuticals is more attractive than Kymera Therapeutics.

Kymera Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.309, suggesting its less volatile than the S&P 500 by 69.074%.

Kymera Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.34% to investors and pays a quarterly dividend of $0.88 per share. Kymera Therapeutics pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Kymera Therapeutics quarterly revenues are $22.1M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Kymera Therapeutics's net income of -$65.6M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Kymera Therapeutics's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 13.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kymera Therapeutics is 61.95x versus 4.23x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.